Lifecore Biomedical, Inc. (NASDAQ:LFCR) Stock Now Rated "Reduce" by Wall Street Brokerages

Lifecore Biomedical logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts collectively rate Lifecore Biomedical “Reduce”: Of five firms covering the stock, two recommend selling and three recommend holding; the average 12-month price target is $6.50.
  • Lifecore reported a quarterly loss of $1.08 per share, substantially worse than the $0.30 loss analysts expected. Revenue of $25.32 million also came in slightly below estimates.
  • Institutional investors own 83.36% of the stock, and several firms increased or initiated positions in recent quarters.
  • Five stocks we like better than Lifecore Biomedical.

Lifecore Biomedical, Inc. (NASDAQ:LFCR - Get Free Report) has received a consensus recommendation of "Reduce" from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and three have given a hold recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $6.50.

LFCR has been the subject of several research analyst reports. Weiss Ratings raised Lifecore Biomedical from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, October 16th. William Blair lowered Lifecore Biomedical from an "outperform" rating to a "hold" rating in a research note on Monday, September 28th. Zacks Research lowered Lifecore Biomedical from a "hold" rating to a "strong sell" rating in a research note on Friday, November 6th. Barrington Research cut Lifecore Biomedical from an "outperform" rating to a "hold" rating in a report on Tuesday, September 29th. Finally, Craig Hallum downgraded Lifecore Biomedical from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 28th.

Get Our Latest Research Report on LFCR

Institutional Investors Weigh In On Lifecore Biomedical

A number of institutional investors and hedge funds have recently bought and sold shares of LFCR. DCF Advisers LLC purchased a new position in Lifecore Biomedical in the 2nd quarter worth approximately $2,229,000. BlackRock Inc. bought a new position in shares of Lifecore Biomedical in the 2nd quarter worth $10,569,000. Tocqueville Asset Management L.P. bought a new position in shares of Lifecore Biomedical in the 2nd quarter worth $796,000. Marshall Wace LLP raised its position in shares of Lifecore Biomedical by 46.0% during the 3rd quarter. Marshall Wace LLP now owns 259,144 shares of the company's stock valued at $1,705,000 after buying an additional 81,673 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in Lifecore Biomedical by 74.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 168,642 shares of the company's stock worth $1,101,000 after acquiring an additional 72,053 shares in the last quarter. 83.36% of the stock is owned by hedge funds and other institutional investors.

Lifecore Biomedical Price Performance

NASDAQ LFCR opened at $6.40 on Thursday. The company's 50 day simple moving average is $5.92 and its two-hundred day simple moving average is $5.41. Lifecore Biomedical has a 1 year low of $3.63 and a 1 year high of $8.98. The stock has a market capitalization of $242.62 million, a PE ratio of -3.44 and a beta of 0.99.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.78). The firm had revenue of $25.32 million for the quarter, compared to analysts' expectations of $25.57 million. On average, research analysts anticipate that Lifecore Biomedical will post -1.83 EPS for the current year.

Lifecore Biomedical Company Profile

(Get Free Report)

Lifecore Biomedical, Inc. is a contract development and manufacturing organization (CDMO) focused on sterile injectable pharmaceutical products. The company works with customers on product development, formulation, analytical testing, regulatory support and commercial-scale manufacturing, including fill-finish services. Lifecore also develops and manufactures hyaluronic acid, a biopolymer used in medical products and other applications. Its capabilities support products in areas such as ophthalmology and orthopedics, as well as pharmaceutical and veterinary uses.

Featured Stories

Analyst Recommendations for Lifecore Biomedical (NASDAQ:LFCR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Lifecore Biomedical Right Now?

Before you consider Lifecore Biomedical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lifecore Biomedical wasn't on the list.

While Lifecore Biomedical currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines